Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IIF vs RDY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RDY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

RDY Overall Winner 6-Pillar Tally: IIF 0 – 5 RDY (1 Tie) Matrix Metrics: IIF 1 – 9 RDY

As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over Morgan Stanley India Investment Fund, Inc. (IIF) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IIF carries a Unified Composite Score of 31.5/100 (SELL) at $23.43 (N/M Forward P/E, N/A operating margin), whereas RDY carries 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin).

  • Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both IIF (31.5/100 SELL) and RDY (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IIF vs RDY
IIF NYSE
Morgan Stanley India Investment Fund, Inc.
Institutional Equity
$23.43
-0.38% 1D
Market Cap $253.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.69β · 21% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 5.0 Fund 31.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 68
RSI-14: 68.0 · SMA20: $22.26 · SMA50: $21.97
RDY NYSE Head-to-Head Winner
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.70
-0.27% 1D
Market Cap $12.3B
TTM Revenue $3.53B
Forward P/E 31.6x
Beta / 30D Vol 0.39β · 24% Vol
Unified Composite Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 68
RSI-14: 68.3 · SMA20: $14.22 · SMA50: $13.10

6-Pillar Scorecard Institutional Category Breakdown (IIF 0 – 5 RDY)

Columns: Metric · IIF · RDY
1. Valuation Multiples RDY
Forward P/E N/M 31.6x
Trailing P/E N/M 40.9x
PEG Ratio N/M 2.01x
EV / Revenue N/M 3.5x
2. Growth & Scale RDY
Revenue Growth (YoY) N/A -1.5%
Earnings Growth (YoY) N/A -35.7%
TTM Revenue (USD) N/A $3.53B
Market Cap $253.3M $12.3B
3. Profitability & Quality RDY
Gross Margin N/A 49.5%
Operating Margin N/A 9.1%
Net Profit Margin N/A 8.5%
Return on Equity (ROE) N/A 7.3%
4. Balance Sheet & Cash Flow RDY
Cash Generation (TTM) N/A $534M EBITDA
Cash Flow Margin N/A 15.1% EBITDA Mgn
Net Cash / Leverage N/A ROE $0.82 Book/Sh · 7.3% ROE
Dividend Yield None (0.00%) 0.57%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat RDY
OpEx & R&D Intensity N/A 40.4% of Rev ($1.43B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IIF (1) vs RDY (9)
Institutional Metric IIF RDY Criterion Row Edge
Market Capitalization
Scale
$253.3M $12.3B Larger Scale RDY
Trailing P/E Ratio
Valuation
N/M 40.9x Lower Multiple RDY
Forward P/E Ratio
Valuation
N/M 31.6x Lower Multiple RDY
Revenue Growth (YoY)
Growth
N/A -1.5% Higher Growth RDY
Operating Margin (TTM)
Profitability
N/A 9.1% Higher Margin RDY
Net Profit Margin
Profitability
N/A 8.5% Higher Margin RDY
Return on Equity (ROE)
Capital Efficiency
N/A 7.3% Higher ROE RDY
52-Week Range Position
Momentum
47% ($20–$28) 78% ($11–$16) Stronger Trend RDY
Beta / 30D Volatility
Risk Regime
0.69β · 21% Vol 0.39β · 24% Vol Lower Realized Risk IIF
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 34.7 / 100 (SELL) Higher Composite RDY
Trailing 12M Revenue (USD)
Operating Scale
N/A $3.53B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 49.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.01x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $534M EBITDA ($0.82 Book/Sh · 7.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RDY +5.14 pp
IIF: +7.33% · RDY: +12.47%
3M Horizon RDY +19.34 pp
IIF: +1.65% · RDY: +20.99%
6M Horizon IIF +1.34 pp
IIF: +9.43% · RDY: +8.09%
1Y Horizon RDY +18.19 pp
IIF: -12.21% · RDY: +5.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IIF vs RDY. Trailing 12-month operating profitability (IIF N/A vs RDY 9.1%) and valuation multiples (IIF N/M vs RDY 31.6x Forward P/E) are benchmarked directly in Pillar 4 below.

IIF ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
RDY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.53B
Gross Margin49.5%
Op. Margin9.1%
ROE / Fwd P/E7.3% · 31.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IIF UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IIF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RDY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IIF Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $253.3M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RDY Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.3B market capitalization and 9.1% operating margin.
OpEx & R&D Reinvestment 40.4% of Rev ($1.43B)
90D Engineering Disclosures 0 Published

Investor FAQ IIF vs RDY Key Questions & Quantitative Answers

As of Nov 16, 2026, Dr. Reddy's Laboratories Limited (RDY) is the stronger overall head-to-head candidate over Morgan Stanley India Investment Fund, Inc. (IIF) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IIF carries a Unified Composite Score of 31.5/100 (SELL) at $23.43 (N/M Forward P/E, N/A operating margin), whereas RDY carries 34.7/100 (SELL) at $14.70 (31.6x Forward P/E, 9.1% operating margin). Defensive Composite Rating Caution: Although RDY compares more favorably head-to-head, both IIF (31.5/100 SELL) and RDY (34.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

RDY leads the Growth & Scale pillar: IIF posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RDY at -1.5% YoY revenue growth and -35.7% YoY earnings growth on $3.53B TTM revenue (49.5% gross margin, 9.1% operating margin). On trailing 12-month operating scale, IIF generates N/A in USD-normalized revenue versus $3.53B for RDY. In operating R&D and SG&A reinvestment, IIF deploys N/A (0 90-day corporate R&D disclosures) versus 40.4% of Rev ($1.43B) (0 disclosures) for RDY.

RDY screens cheaper on headline valuation multiples. IIF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RDY trades at 31.6x Forward P/E, 40.9x Trailing P/E, 2.01x PEG, and 3.5x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IIF (N/A ROE) versus RDY (7.3% ROE) capital efficiency.

In options market volatility and institutional positioning, IIF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.69β · 21% Vol realized risk). By comparison, RDY carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.